Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab vs BAT in Chronic GVHD
NCT06821542Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Incyte. Primary endpoint: Objective Response at 6 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06821542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821542.